The board of directors of The United Laboratories International Holdings Limited announced that on 8 September 2023, the application for the clinical trial of class 1 innovative new drug UBT251 Injection self-developed by The United Bio-Technology (Hengqin) Co. Ltd., a wholly-owned subsidiary of the Company, on indication of non-alcoholic fatty liver disease (NAFLD) was approved by China National Medical Products Administration, with reference number of CXHL2300700. UBT251 is a long-acting triple agonist of GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulinotropic polypeptide) /GCG (glucagon).

As shown by the early human clinical trial results of drugs with the same type of targets, after a dosage period of more than 48 weeks, they can effectively reduce blood glucose and body weight, reduce liver fat and improve blood pressure and blood lipids, showing significant improvement in patients' overall metabolism. At present, the Company is the first enterprise in China and the second enterprise in the world to be approved for the clinical trials of a long-acting triple agonist of GLP-1/GIP/GCG prepared by chemical synthetic polypeptide. UBT251 Injection on indications of adult type 2 diabetes and overweight or obesity have been approved for clinical trial on 29 August 2023 and 1 September 2023 respectively.